



29 April 2014  
29 April 2014  
P.U. (A) 116

WARTA KERAJAAN PERSEKUTUAN  
*FEDERAL GOVERNMENT  
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)  
(NO. 2) 2014

*POISONS (AMENDMENT OF POISONS LIST)  
(NO. 2) ORDER 2014*



DISIARKAN OLEH/  
*PUBLISHED BY*  
JABATAN PEGUAM NEGARA/  
*ATTORNEY GENERAL'S CHAMBERS*

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2014

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

**Nama**

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) (No. 2) 2014**.

**Pindaan Jadual Pertama**

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Azelaic Acid” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Azilsartan	-	All preparations";				

(ii) dalam butiran "Antihistamines; the following:", dengan memasukkan selepas butiran "Bamipine" butiran "Bilastine";

(iii) dengan memasukkan selepas butiran "Dantrolene; its salts" dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Dapagliflozin	-	All preparations";				

- (iv) dengan memasukkan selepas butiran “Dolasetron Mesylate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dolutegravir	-	All preparations”;				

- (v) dengan memasukkan selepas butiran “Lithium salts for therapeutic use” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lixisenatide	-	All preparations”;				

- (vi) dengan memasukkan selepas butiran “Minoxidil; its salts; its derivatives” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mipomersen sodium	-	All preparations”;				

- (vii) dengan memasukkan selepas butiran “Nystatin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ocriplasmin	-	All preparations”;				

- (viii) dengan memasukkan selepas butiran “Octreotide; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ofatumumab	-	All preparations”;				

- (ix) dengan memasukkan selepas butiran “Pentoxifylline” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Perampanel	-	All preparations”;				

- (x) dalam butiran “Racecadotril”, dengan menggantikan “Racecadotril” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Racecadotril	-	-	All preparations”; dan			

- (xi) dengan memasukkan selepas butiran “Vigabatrin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vilanterol	-	All preparations”; dan				

- (b) dalam Lampiran Senarai Racun—

- (i) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”, dengan memasukkan selepas butiran “Octreotide” butiran “Ofatumumab”;

- (ii) dalam senarai “**Anti-asthmatics:**”, dengan memasukkan selepas butiran “Tulobuterol” butiran “Vilanterol”;
- (iii) dalam senarai “**Anticonvulsants:**”, dengan memasukkan selepas butiran “Paramethadione” butiran “Perampanel”;
- (iv) dalam senarai “**Antidiabetics:**”—
  - (A) dengan memasukkan selepas butiran “Chlorpropamide; its salts” butiran “Dapagliflozin”; dan
  - (B) dengan memasukkan selepas butiran “Liraglutide” butiran “Lixisenatide”;
- (v) dalam senarai “**Antihistamines:**”, dengan memasukkan selepas butiran “Bamipine” butiran “Bilastine”;
- (vi) dalam senarai “**Antihypertensives:**”, dengan memasukkan selepas butiran “Aliskiren” butiran “Azilsartan”;
- (vii) dalam senarai “**Antiviral agents:**”, dengan memasukkan selepas butiran “Didanosine” butiran “Dolutegravir”; dan

(viii) dalam senarai “**Miscellaneous:**”—

(A) dengan memasukkan selepas butiran “Metyrapone; its salts” butiran “Mipomersen sodium”; dan

(B) dengan memasukkan selepas butiran “Nux Vomica, alkaloids of” butiran “Ocriplasmin”.

Dibuat 9 April 2014  
[KK(R)608(14); PN(PU2)172/XII]

DATUK SERI DR. S. SUBRAMANIAM  
*Menteri Kesihatan*

## POISONS ACT 1952

## POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2014

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

**Citation**

1. This order may be cited as the **Poisons (Amendment of Poisons List) (No. 2) Order 2014**.

**Amendment of First Schedule**

2. The Poisons Act 1952 is amended in the First Schedule—

(a) in the Poisons List—

- (i) by inserting after the item “Azelaic Acid” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Azilsartan	-	All preparations”;					

- (ii) under the item “Antihistamines; the following:”, by inserting after the item “Bamipine” the item “Bilastine”;
- (iii) by inserting after the item “Dantrolene; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dapagliflozin	-	All preparations”;				

- (iv) by inserting after the item “Dolasetron Mesylate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dolutegravir	-	All preparations”;				

- (v) by inserting after the item “Lithium salts for therapeutic use” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lixisenatide	-	All preparations”;				

(vi) by inserting after the item “Minoxidil; its salts; its derivatives” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Mipomersen sodium	-	All preparations”;				

(vii) by inserting after the item “Nystatin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ocriplasmin	-	All preparations”;				

(viii) by inserting after the item “Octreotide; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Ofatumumab	-	All preparations”;				

(ix) by inserting after the item “Pentoxifylline” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Perampanel	-	All preparations”;				

(x) in the item “Racecadotril”, by substituting for “Racecadotril” and the particulars relating to it the following particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Racecadotril	-	-	All preparations”;			and

(xi) by inserting after the item “Vigabatrin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vilanterol	-	All preparations”;				and

- (b) in the Appendix to the Poisons List—
- (i) in the list of “**Antineoplastic agents and Immunosuppressants:**”, by inserting after the item “Octreotide” the item “Ofatumumab”;
  - (ii) in the list of “**Anti-asthmatics:**”, by inserting after the item “Tulobuterol” the item “Vilanterol”;
  - (iii) in the list of “**Anticonvulsants:**”, by inserting after the item “Paramethadione” the item “Perampanel”;
  - (iv) in the list of “**Antidiabetics:**”—
    - (A) by inserting after the item “Chlorpropamide; its salts” the item “Dapagliflozin”; and
    - (B) by inserting after the item “Liraglutide” the item “Lixisenatide”;
  - (v) in the list of “**Antihistamines:**”, by inserting after the item “Bamipine” the item “Bilastine”;
  - (vi) in the list of “**Antihypertensives:**”, by inserting after the item “Aliskiren” the item “Azilsartan”;
  - (vii) in the list of “**Antiviral agents:**”, by inserting after the item “Didanosine” the item “Dolutegravir”; and

(viii) in the list “**Miscellaneous:**”—

(A) by inserting after the item “Metyrapone; its salts” the item “Mipomersen sodium”; and

(B) by inserting after the item “Nux Vomica, alkaloids of” the item “Ocriplasmin”.

Made 9 April 2014  
[KK(R)608(14); PN(PU2)172/XII]

DATUK SERI DR. S. SUBRAMANIAM  
*Minister of Health*